Celon Pharma S.A. (WSE:CLN)
20.50
-0.40 (-1.91%)
Jun 16, 2026, 3:00 PM CET
Celon Pharma Employees
Celon Pharma had 564 employees as of March 31, 2026. The number of employees decreased by 3 or -0.53% compared to the same quarter last year.
Employees
564
Change
-3
Growth
-0.53%
Revenue / Employee
398.58K PLN
Profits / Employee
-216.24K PLN
Market Cap
1.13B
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Mar 31, 2026 | 564 | -3 | -0.53% | 564 | 0 |
| Sep 30, 2025 | 566 | 4 | 0.71% | 566 | 0 |
| Jun 30, 2025 | 568 | 2 | 0.35% | 568 | 0 |
| Mar 31, 2025 | 567 | -1 | -0.18% | 567 | 0 |
| Dec 31, 2024 | 558 | 43 | 8.35% | 553 | 5 |
| Sep 30, 2024 | 562 | 49 | 9.55% | 562 | 0 |
| Jun 30, 2024 | 566 | 50 | 9.69% | 566 | 0 |
| Mar 31, 2024 | 568 | 47 | 9.02% | 568 | 0 |
| Dec 31, 2023 | 515 | -8 | -1.53% | 515 | 0 |
| Sep 30, 2023 | 513 | -10 | -1.91% | 513 | 0 |
| Jun 30, 2023 | 516 | 12 | 2.38% | 516 | 0 |
| Mar 31, 2023 | 521 | 17 | 3.37% | 521 | 0 |
| Dec 31, 2022 | 523 | 35 | 7.17% | 523 | 0 |
| Sep 30, 2022 | 523 | 5 | 0.97% | 523 | 0 |
| Jun 30, 2022 | 504 | -10 | -1.95% | 504 | 0 |
| Mar 31, 2022 | 504 | 6 | 1.20% | 504 | 0 |
| Dec 31, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Sep 30, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Jun 30, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Mar 31, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Diagnostyka | 8,645 |
| NEUCA | 5,339 |
| Centrum Medyczne ENEL-MED | 1,270 |
| Mercator Medical | 950 |
| Selvita | 691 |
| Voxel | 356 |
| Synektik Spólka Akcyjna | 231 |
| Scope Fluidics | 157 |
Celon Pharma News
- 26 days ago - Celon Pharma Quarterly report: Q1 2026 - Filings
- 7 weeks ago - Celon Pharma Annual report: Q4 2025 - Filings
- 7 months ago - Celon Pharma Quarterly report: Q3 2025 - Filings
- 7 months ago - Celon Pharma Slides: Q3 2025 - Filings
- 9 months ago - Celon Pharma Quarterly report: Q2 2025 - Filings
- 9 months ago - Celon Pharma Slides: Q2 2025 - Filings
- 1 year ago - Strong Proof-of-Concept Data from Phase 2 Trial of PDE10A Inhibitor (CPL'36), a Novel Once-Daily Treatment of Levodopa-Induced Dyskinesia in Parkinson's Disease - Benzinga